BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 1366927)

  • 1. The advent of recombinant pertussis vaccines.
    Burnette WN
    Biotechnology (N Y); 1990 Nov; 8(11):1002-5. PubMed ID: 1366927
    [No Abstract]   [Full Text] [Related]  

  • 2. Detoxification of pertussis toxin by site-directed mutagenesis: a review of connaught strategy to develop a recombinant pertussis vaccine.
    Loosmore S; Cockle S; Zealey G; Boux H; Phillips K; Fahim R; Klein M
    Mol Immunol; 1991 Mar; 28(3):235-8. PubMed ID: 1708104
    [No Abstract]   [Full Text] [Related]  

  • 3. Towards third-generation whooping cough vaccines.
    Rappuoli R; Pizza M; Podda A; De Magistris MT; Nencioni L
    Trends Biotechnol; 1991 Jul; 9(7):232-8. PubMed ID: 1370047
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of pertussis toxin encoded by ptx genes from Bordetella bronchiseptica to model the effects of antigenic drift of pertussis toxin on antibody neutralization.
    Hausman SZ; Burns DL
    Infect Immun; 2000 Jun; 68(6):3763-7. PubMed ID: 10816544
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Construction of the genetically attenuated bacteria Bordetella pertussis devoid of dermonecrotic toxin activity and producing modified nontoxic pertussis toxin form].
    Siniashina LN; Siniashina LS; Semin EG; Amelina IP; Karataev GI
    Mol Gen Mikrobiol Virusol; 2010; (3):31-6. PubMed ID: 20886687
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Engineering bacterial toxin for the development of new vaccine against pertussis.
    Bartoloni A; Pizza M; Gross R; Perugini M; Arico B; Domenighini M; Rappuoli R
    Tokai J Exp Clin Med; 1988; 13 Suppl():217-22. PubMed ID: 2483870
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bordetella pertussis Strain Lacking Pertactin and Pertussis Toxin.
    Williams MM; Sen K; Weigand MR; Skoff TH; Cunningham VA; Halse TA; Tondella ML;
    Emerg Infect Dis; 2016 Feb; 22(2):319-322. PubMed ID: 26812174
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Cellular and acellular anti-pertussis vaccines].
    Locht C
    Ann Pharm Fr; 2001 May; 59(3):198-205. PubMed ID: 11427821
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evolution of whooping cough bacterium may reduce vaccine effectiveness.
    Riedmann EM
    Hum Vaccin Immunother; 2014; 10(6):1430. PubMed ID: 25396233
    [No Abstract]   [Full Text] [Related]  

  • 10. Construction and evaluation of Bordetella pertussis live attenuated vaccine strain BPZE1 producing Fim3.
    Debrie AS; Coutte L; Raze D; Mooi F; Alexander F; Gorringe A; Mielcarek N; Locht C
    Vaccine; 2018 Mar; 36(11):1345-1352. PubMed ID: 29433898
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bordetella pertussis and pertactin-deficient clinical isolates: lessons for pertussis vaccines.
    Hegerle N; Guiso N
    Expert Rev Vaccines; 2014 Sep; 13(9):1135-46. PubMed ID: 24953157
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evolution of Bordetella pertussis.
    He Q
    Pediatr Infect Dis J; 2016 Aug; 35(8):915-7. PubMed ID: 27213264
    [No Abstract]   [Full Text] [Related]  

  • 13. [Modern strains of Bordetella pertussis: immunobiological properties and vaccine improvement].
    Shinkarev AS; Mertsalova NU; Mazurova IK; Borisova OIu; Zakharova NS; Ozeretskovskaia MN; Zaĭtsev EM; Poddubikov AV; Britsina MV; Bazhanova IG
    Zh Mikrobiol Epidemiol Immunobiol; 2007; (4):20-5. PubMed ID: 17886371
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunogenicity and protective efficacy of a recombinant filamentous haemagglutinin from Bordetella pertussis.
    Knight JB; Huang YY; Halperin SA; Anderson R; Morris A; Macmillan A; Jones T; Burt DS; Van Nest G; Lee SF
    Clin Exp Immunol; 2006 Jun; 144(3):543-51. PubMed ID: 16734625
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Components of acellular pertussis vaccines.
    Preston NW; Matthews RC
    Lancet; 1996 Mar; 347(9003):764. PubMed ID: 8602023
    [No Abstract]   [Full Text] [Related]  

  • 16. Use of Bordetella bronchiseptica and Bordetella pertussis as live vaccines and vectors for heterologous antigens.
    Stevenson A; Roberts M
    FEMS Immunol Med Microbiol; 2003 Jul; 37(2-3):121-8. PubMed ID: 12832115
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Attenuated Bordetella pertussis BPZE1 as a live vehicle for heterologous vaccine antigens delivery through the nasal route.
    Li R; Lim A; Alonso S
    Bioeng Bugs; 2011; 2(6):315-9. PubMed ID: 22067832
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of different forms of adenylate cyclase toxin of Bordetella pertussis on protection afforded by an acellular pertussis vaccine in a murine model.
    Cheung GY; Xing D; Prior S; Corbel MJ; Parton R; Coote JG
    Infect Immun; 2006 Dec; 74(12):6797-805. PubMed ID: 16982827
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Protective immunogenicity of synthetic peptides selected from the amino acid sequence of Bordetella pertussis toxin subunit S1.
    Askelöf P; Rodmalm K; Wrangsell G; Larsson U; Svenson SB; Cowell JL; Undén A; Bartfai T
    Dev Biol Stand; 1991; 73():111-20. PubMed ID: 1778305
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Polymorphisms of the fimbria fim3 gene of Bordetella pertussis strains isolated in Canada.
    Tsang RS; Lau AK; Sill ML; Halperin SA; Van Caeseele P; Jamieson F; Martin IE
    J Clin Microbiol; 2004 Nov; 42(11):5364-7. PubMed ID: 15528744
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.